Patient-Centered Interventions to Improve Adherence to Statins: A Narrative Synthesis of Systematically Identified Studies.
Poor adherence to statins increases cardiovascular disease risk. We systematically identified 32 controlled studies that assessed patient-centered interventions designed to improve statin adherence. The limited number of studies and variation in study characteristics precluded strict quality criteria or meta-analysis. Cognitive education or behavioural counselling delivered face-to-face multiple times consistently improved statin adherence compared with control groups (7/8 and 3/3 studies, respectively). None of four studies using medication reminders and/or adherence feedback alone reported significantly improved statin adherence. Single interventions that improved statin adherence but were not conducted face-to-face included cognitive education in the form of genetic test results (two studies) and cognitive education via a website (one study). Similar mean adherence measures were reported for 17 intervention arms and were thus compared in a sub-analysis: 8 showed significantly improved statin adherence, but effect sizes were modest (+7 to +22 % points). In three of these studies, statin adherence improved despite already being high in the control group (82-89 vs. 57-69 % in the other studies). These three studies were the only studies in this sub-analysis to include cognitive education delivered face-to-face multiple times (plus other interventions). In summary, the most consistently effective interventions for improving adherence to statins have modest effects and are resource-intensive. Research is needed to determine whether modern communications, particularly mobile health platforms (recently shown to improve medication adherence in other chronic diseases), can replicate or even enhance the successful elements of these interventions while using less time and fewer resources.
AstraZeneca Gothenburg, Mölndal, Sweden. Magnus.Jornten-Karlsson@astrazeneca.com.
Magnus
M
Jörntén-Karlsson
Research Evaluation Unit, Oxford PharmaGenesis, Oxford, UK.
Stéphane
S
Pintat
Research Evaluation Unit, Oxford PharmaGenesis, Oxford, UK.|School of Medicine, Pharmacy and Health, Durham University, Stockton-on-Tees, UK.
Michael
M
Molloy-Bland
AstraZeneca Gothenburg, Mölndal, Sweden.
Staffan
S
Berg
AstraZeneca Gothenburg, Mölndal, Sweden.
Matti
M
Ahlqvist
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D018802:Patient-Centered Care; D055815:Young Adult
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
Ann Pharmacother. 2010 Sep;44(9):1410-21
20702755
JAMA Intern Med. 2014 Feb 1;174(2):186-93
24247275
Clin Ther. 2001 Jun;23(6):970-80
11440296
Diabetes Educ. 2015 Feb;41(1):136-46
25486932
Am J Cardiol. 2012 Sep 1;110(5):666-72
22621795
Patient Prefer Adherence. 2012;6:805-14
23152673
Pharmacogenomics J. 2014 Jun;14(3):272-80
23979174
Can J Clin Pharmacol. 2003 Fall;10(3):101-6
14506507
Am Heart J. 2012 Apr;163(4):657-65.e1
22520532
Stroke. 2014 Feb;45(2):515-9
24385269
J Clin Pharmacol. 2004 Jun;44(6):632-9
15145971
Lancet. 2010 Nov 13;376(9753):1670-81
21067804
Br J Clin Pharmacol. 2013 Sep;76 Suppl 1:47-55
24007452
Dis Manag. 2006 Apr;9(2):102-14
16620196
Ann Pharmacother. 2007 Nov;41(11):1805-11
17925498
Ann Pharmacother. 2013 Nov;47(11):1448-56
24259595
Pharmacotherapy. 2010 Aug;30(8):766-75
20653352
Patient Educ Couns. 2014 Dec;97(3):310-26
25264309
Patient Prefer Adherence. 2012;6:323-9
22563240
Clin Ther. 2012 May;34(5):1084-91
22554973
Diabetes Care. 2008 Sep;31(9):1717-22
18523144
QJM. 2011 Feb;104(2):109-24
20934984
Am J Manag Care. 2013 Apr 01;19(4):e133-9
23725451
Health Aff (Millwood). 2014 Aug;33(8):1444-52
25092847
J Cardiopulm Rehabil Prev. 2012 Nov-Dec;32(6):394-9
23143689
J Med Internet Res. 2015 Feb 24;17(2):e52
25803266
Int J Gen Med. 2013 Jul 30;6:647-55
23935386
BMC Fam Pract. 2009 Jun 30;10:48
19566950
Cerebrovasc Dis Extra. 2014 Dec 11;4(3):221-34
25598772
Ann Pharmacother. 2010 Dec;44(12):1905-13
21119098
Drugs. 2013 May;73(6):545-62
23588595
Popul Health Manag. 2009 Oct;12(5):241-54
19848566
Front Pharmacol. 2013 May 29;4:69
23755014
Am J Med. 2009 Jul;122(7):647-55
19559167
J Pers Med. 2014 Mar 27;4(2):147-62
25563221
J Am Pharm Assoc (2003). 2013 Nov-Dec;53(6):576-83
24185429
Eur J Clin Pharmacol. 2011 Apr;67(4):407-14
21152908
JAMA. 1998 May 13;279(18):1458-62
9600480
JAMA. 2002 Jul 24-31;288(4):462-7
12132976
Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011
25412402
Pharmacoepidemiol Drug Saf. 2006 Feb;15(2):115-21
16342302
Br J Clin Pharmacol. 2012 May;73(5):691-705
22486599
Am J Manag Care. 2010 Feb;16(2):116-22
20148616
Cardiovasc Drugs Ther. 2005 Dec;19(6):437-40
16435071
Perm J. 2010 Spring;14(1):4-10
20740125
Cholesterol. 2010;2010:383281
21490915
Pharmacotherapy. 2000 Apr;20(4):410-6
10772372
Eur J Clin Pharmacol. 2009 Oct;65(10):1013-24
19529927